/ADCT

ADC Therapeutics SA

ADCT

$1.07USD↓-3.60%-0.04 today

MARKET CAP

136.6M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1

$5

AI Summary

Stalk

Buy NowMedium

ADCT has formed an early post-capitulation base in Stage 1 with clear exhaustion after a deep washout. The chart is extreme oversold, and RSI is recovering from lows. Price is tightly holding above the rising 9EMA and 21EMA, confirming support. Mean‐reversion rules in Stage 1 mandate a medium‐term bullish bias and open a buy‐now opportunity at short‐term EMA support.

↑Q1 net product revenues rose 15% YoY to $20M, indicating stable demand for Zynlanta.
↑$231M cash runway supports trials and operations through 2028, reducing dilution risk.
↓Q1 net loss narrowed to $33M vs $38.6M YoY but still indicates negative profitability.

Full analysis →

Buying

5

institutions

Selling

5

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	7.02 M	7.51 M	+769.35 K	-68.0%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUY	3.68 M	3.93 M	+267.01 K	-69.2%	0.00%
MM Millennium Management LLC Q2 2026	SELL	3.05 M	3.26 M	+-204.62 K	-73.3%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	2.05 M	2.20 M	+1.65 M	+46.6%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	658.12 K	704.19 K	+420.49 K	-21.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	152.54 K	157.12 K	+-336.54 K	-91.2%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUYNEW	36.88 K	39.47 K	+36.88 K	+0.0%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	431.00	462.00	+-1.06 K	-91.7%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	0.00	0.00	+-299.28 K	-100.0%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	0.00	0.00	+-77.95 K	-100.0%	0.00%